<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479570</url>
  </required_header>
  <id_info>
    <org_study_id>A8361015</org_study_id>
    <nct_id>NCT00479570</nct_id>
  </id_info>
  <brief_title>Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.</brief_title>
  <official_title>Phase 2A Multi-Centre, Double Blind, Placebo Controlled 3-Way Cross-Over Study To Investigate The Effect Of Single Doses Of PF-00446687 On Sexual Arousal And Sexual Desire In Women Suffering From Female Sexual Dysfunction (FSD).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on
      acute sexual arousal and sexual interest in post menopausal females, as well as examining the
      safety and toleration of the drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess effect of single doses of PF-00446687 on acute sexual arousal and sexual interest, using questionnaires, in post menopausal women suffering from Female Sexual Dysfunction. A diary will be completed for 7 days following the 3 dosing days.</measure>
    <time_frame>From day of dosing until 7 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess effect of single doses on medium term (1 week) sexual arousal and interest.</measure>
    <time_frame>Until 7 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess variability of response and repeatability of design between 2 similar doses.</measure>
    <time_frame>Comparison of response to be assessed until 7 days post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>If possible assess the effect of PF-00446687 on vaginal blood flow on day 1 of each study period.</measure>
    <time_frame>Day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess PK , safety and toleration on day 1 of each study period.</measure>
    <time_frame>Day of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Female Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Study period 1, 2 or 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Study period 1, 2 or 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00446687</intervention_name>
    <description>Single 200mg dose</description>
    <arm_group_label>Study period 1, 2 or 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Study period 1, 2 or 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who have evidence of Female Sexual Arousal Disorder.

          -  Women who experience personal distress due to Female Sexual Dysfunction.

          -  Post menopausal women aged between 45 and 65 years.

        Exclusion Criteria:

          -  Women whose sexual dysfunction is limited to certain types of stimulation, situation
             or specific partners.

          -  Women who experience pain with sexual intercourse or who have a sexual aversion
             disorder.

          -  Women suffering from female sexual dysfunction where the cause is treatable, for
             example inadequately controlled diabetes or thyroid dysfunction.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kobenhavn OE</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Danderyd</city>
        <zip>S-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8361015&amp;StudyName=Study%20To%20Investigate%20Effect%20Of%20A%20New%20Drug%20%28PF-00446687%29%20In%20Post-Menopausal%20Women%20Who%20Suffer%20From%20Sexual%20Dysfunction.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <last_update_submitted>April 7, 2009</last_update_submitted>
  <last_update_submitted_qc>April 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

